Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia

使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径

基本信息

项目摘要

Project Summary/Abstract Managing tumor recurrence and spread is a major challenge in breast cancer. This scenario is further aggravated for women with diabetes as numerous epidemiological studies show that women with type 2 diabetes are at significantly greater risk of developing, relapsing with, and dying from breast cancer compared to women who are not diabetic. Studies show that hyperinsulinemia associated with type 2 diabetes is a significant contributing factor for the mortality seen in breast cancer patients, suggesting an important need for effective therapies that inhibit tumor cell proliferation under hyperinsulinemic conditions. Our early studies showed that cdk4 knock- out mice fail to develop breast cancers driven by the ERBB2 or RAS oncogenes suggesting that CDK4/6 inhibitors may be effective therapeutic agents for certain breast cancers. The approval of CDK4/6 inhibitors as breast cancer therapeutics validated this theory. Another kinase which plays a critical role in insulin signaling and cancer progression is NUAK1/ARK5 which belongs to the AMPK gene family which regulate metabolism. The normal physiological role played by NUAK1/ARK5 in the whole organism was studied using muscle-specific knock-out mice which showed that NUAK1 controls glucose metabolism through regulation of the insulin signaling. Thus, when these knock-out mice were fed a high fat diet, they exhibited a lower fasting blood glucose level, greater glucose tolerance, higher insulin sensitivity, and higher concentrations of muscle glycogen compared to control mice suggesting that inhibition of ARK5/NUAK1 can overcome the effects of hyperglycemia. Interestingly, ARK5 was originally identified as a metastasis gene and its over-expression has been shown to promote metastasis of several tumor types. To achieve the goal of inhibiting breast tumor cell growth and metabolism, we developed a potent dual inhibitor of CDK4 and ARK5 (ON123300), which was a very effective inhibitor of breast tumor growth. In addition, this compound has shown a profound effect on high sugar diet-induced tumor development and metastasis in a Drosophila model system. In this application, we propose to extend these studies to mouse models of hyperinsulinemia (MKR mice), developed by Dr. LeRoith and PDX models of Triple Negative Breast cancer (TNBCs) developed by Dr. Irie. The aims are: (1) To test the effects of ON123300 on the growth and metastasis of mammary tumors in MKR mice which exhibit hyperinsulinemic, pre-diabetic phenotype; (2) To examine the effects of hyperinsuminemia on the growth and metastasis of PDX breast tumors and utilize the models with the highest relative levels of ARK5 to examine the therapeutic value of ON123300; and (3) To use the newly developed Multiplexed-kinase Inhibitor Beads (MIB) and “Cancer Toolkit gain-of-function” (CTK) technologies to determine whether breast cancer cells develop resistance to ON123300 upon prolonged exposure and to determine the nature of signaling pathways that might be the root cause of such resistance.
项目概要/摘要 控制肿瘤复发和扩散是乳腺癌的主要挑战。这种情况进一​​步加剧 对于患有糖尿病的女性来说,大量流行病学研究表明,患有 2 型糖尿病的女性处于 与患有乳腺癌的女性相比,罹患乳腺癌、复发乳腺癌和死于乳腺癌的风险显着增加 不是糖尿病患者。研究表明,与 2 型糖尿病相关的高胰岛素血症是导致 2 型糖尿病的重要因素。 乳腺癌患者死亡率的一个因素,表明迫切需要有效的治疗方法 在高胰岛素条件下抑制肿瘤细胞增殖。我们的早期研究表明 cdk4 敲除 ERBB2 或 RAS 癌基因驱动的小鼠未能患上乳腺癌,这表明 CDK4/6 抑制剂可能是某些乳腺癌的有效治疗剂。 CDK4/6抑制剂获批 乳腺癌治疗验证了这一理论。另一种在胰岛素信号传导中发挥关键作用的激酶 癌症进展是NUAK1/ARK5,属于调节代谢的AMPK基因家族。 研究了 NUAK1/ARK5 在整个生物体中发挥的正常生理作用 肌肉特异性基因敲除小鼠显示 NUAK1 通过以下方式控制葡萄糖代谢: 胰岛素信号传导的调节。因此,当这些基因敲除小鼠被喂食高脂肪饮食时,它们 表现出较低的空腹血糖水平、较高的葡萄糖耐量、较高的胰岛素敏感性,以及 与对照小鼠相比,肌糖原浓度较高,表明抑制 ARK5/NUAK1可以克服高血糖的影响。有趣的是,ARK5最初被识别为 作为转移基因,其过度表达已被证明可促进多种肿瘤的转移 类型。为了达到抑制乳腺肿瘤细胞生长和代谢的目标,我们开发了一种强效的双重 CDK4 和 ARK5 抑制剂 (ON123300),是一种非常有效的乳腺肿瘤生长抑制剂。在 此外,这种化合物对高糖饮食诱导的肿瘤发展具有深远的影响, 果蝇模型系统中的转移。在此应用中,我们建议将这些研究扩展到小鼠模型 LeRoith 博士开发的高胰岛素血症(MKR 小鼠)和三阴性乳腺癌 PDX 模型 (TNBC)由入江博士开发。目的是:(1)测试ON123300对生长和转移的影响 MKR 小鼠乳腺肿瘤表现出高胰岛素血症、糖尿病前期表型; (2) 检查 高胰岛素血症对 PDX 乳腺肿瘤生长和转移的影响并利用模型 ARK5的最高相对水平来检验ON123300的治疗价值; (3) 使用新的 开发了多重激酶抑制剂珠(MIB)和“癌症工具包功能获得”(CTK)技术 确定乳腺癌细胞在长期接触 ON123300 后是否会对 ON123300 产生耐药性,并 确定可能是这种耐药性根本原因的信号通路的性质。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CDK4: a master regulator of the cell cycle and its role in cancer.
  • DOI:
    10.18632/genesandcancer.221
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Baker, Stacey J;Poulikakos, Poulikos I;Irie, Hanna Y;Parekh, Samir;Reddy, E Premkumar
  • 通讯作者:
    Reddy, E Premkumar
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

E Premkumar Reddy其他文献

IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled
白细胞介素 3 信号传导以及 Src 激酶、JAK 和 STAT 的作用:一个隐蔽的联络被揭示
  • DOI:
    10.1038/sj.onc.1203594
  • 发表时间:
    2000-05-25
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    E Premkumar Reddy;Anita Korapati;Priya Chaturvedi;Sushil Rane
  • 通讯作者:
    Sushil Rane
Janus kinases: components of multiple signaling pathways
Janus 激酶:多条信号通路的组成部分
  • DOI:
    10.1038/sj.onc.1203925
  • 发表时间:
    2000-11-20
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Sushil G Rane;E Premkumar Reddy
  • 通讯作者:
    E Premkumar Reddy
The myb gene family in cell growth, differentiation and apoptosis
细胞生长、分化和凋亡中的 myb 基因家族
  • DOI:
    10.1038/sj.onc.1202839
  • 发表时间:
    1999-05-13
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Il-Hoan Oh;E Premkumar Reddy
  • 通讯作者:
    E Premkumar Reddy
JAKs, STATs and Src kinases in hematopoiesis
造血过程中的 JAKs、STATs 和 Src 激酶
  • DOI:
    10.1038/sj.onc.1205398
  • 发表时间:
    2002-05-21
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Sushil G Rane;E Premkumar Reddy
  • 通讯作者:
    E Premkumar Reddy
Signaling by dual specificity kinases
双特异性激酶的信号传导
  • DOI:
    10.1038/sj.onc.1202251
  • 发表时间:
    1998-09-22
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    N Dhanasekaran;E Premkumar Reddy
  • 通讯作者:
    E Premkumar Reddy

E Premkumar Reddy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('E Premkumar Reddy', 18)}}的其他基金

Targeting FL3 and SRC kinases for AML therapy
靶向 FL3 和 SRC 激酶进行 AML 治疗
  • 批准号:
    10658259
  • 财政年份:
    2023
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
  • 批准号:
    10199970
  • 财政年份:
    2020
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
  • 批准号:
    10029076
  • 财政年份:
    2020
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
  • 批准号:
    10457279
  • 财政年份:
    2020
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting CDK4 in TGS-B Inactivated Gastrointestinal Cancers
TGS-B 灭活胃肠道癌中靶向 CDK4
  • 批准号:
    8744873
  • 财政年份:
    2013
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
  • 批准号:
    8985660
  • 财政年份:
    2012
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
  • 批准号:
    8787991
  • 财政年份:
    2012
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
  • 批准号:
    8435360
  • 财政年份:
    2012
  • 资助金额:
    $ 51.47万
  • 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
  • 批准号:
    8238575
  • 财政年份:
    2012
  • 资助金额:
    $ 51.47万
  • 项目类别:
Role of C-myb in Hematopoiesis and Cancer
C-myb 在造血和癌症中的作用
  • 批准号:
    7629613
  • 财政年份:
    2007
  • 资助金额:
    $ 51.47万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 51.47万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 51.47万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 51.47万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 51.47万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了